Tai Diagnostics, a life sciences firm developing tests for transplanted organs, raises $8.2m.

Medical College of Wisconsin spinout Tai Diagnostics has secured $8.2m in a series A round to support development of its organ transplant testing kits.

The round was led by US-based venture firm Venture Investors and supported by other unnamed backers.

Tai Diagnostics, founded earlier this year, will be using the cash to further develop its cell free DNA-based technology which helps monitor transplanted organs. As part of the round, life sciences management veteran Frank Langley will join Tai as its CEO.

Loren Peterson, managing director at Venture Investors, said: “We are very excited to participate in the TAI Diagnostics financing and feel confident about the ability of its novel cfDNA technology to play a major role in the transplant diagnostics market. Our firm also knows Frank Langley well, and his deep and relevant experience in transplant diagnostics make us even more confident in TAI Diagnostics’ future.”